EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy

Giovanni Almanzar iD, Anna Broderdörp, Juliane Mees iD, Manfred Frey iD, Felix J F Herth iD, Marc A Schneider iD, Frederik Trinkmann iD, Martina Prelog

Journal of Asthma and Allergy · 2026-02 · Volume 19 · 1-15

DOI: 10.2147/jaa.s547038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-02. Verfasst von Giovanni Almanzar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Wuerzburg, Wuerzburg, Germany. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

It has been proposed that patients with asthma on monoclonal antibodies (mAb) targeting Interleukin-5 (IL-5), IL-4/IL-13 pathways or IgE may demonstrate insufficient defense against viral infections requiring strong T-helper-cell-type-1-(Th1) for neutralizing antibody production and cytotoxic CD8+ T-cell responses for efficient clearance of the viral pathogens. It is a matter of debate whether those mAb may impair the immune response against SARS-CoV-2-spike-protein by interacting with cytokines critical for B-cell differentiation and antibody maturation. This controlled cross-sectional cohort study aimed to characterize the mucosal and serum humoral immune response as well as the cellular reactivity against spike-protein in asthma patients on mAb or on conventional treatment (conv). Materials and Methods: Nasal and serum anti-spike-IgG and -IgA concentrations, avidity, neutralizing IgG and cytokine profiles were assessed using serological and neutralization assays and bead-based cytokine detection in nine patients on mAb matched to nine patients on conv who had received COVID-19-mRNA-vaccination. Proportions of spike-induced subpopulations of T- and B-cells were investigated by flow cytometry.

Results

Blockade of IL-5 and IL-5 receptor showed higher serum and nasal concentrations of anti-spike-IgA against recombinant-binding-domain-(RBD) and spike-protein-1-(S1) and similar concentrations of anti-spike-IgG compared to mAb or conv therapy. A spike-specific CD8+ T-cell-driven immune response with increased cytotoxic markers was seen in anti-IL-5 treatments. Baseline Th1 responses correlated with IFNγ- and TNFα-production in supernatants of spike-protein-stimulated cultures in all patients.

Conclusion

The findings indicate a significant specific adaptive immune response to SARS-CoV-2-spike-protein exposures by Th1- and Th2-driven responses with a significant response by serum and mucosal anti-S1 and anti-RBD-IgA in anti-IL-5-treated patients compared to IL-4/IL-13-targeting, anti-IgE or conventional therapies. Thus, based on the results it may be expected that immunogenicity of COVID-19-mRNA-vaccines or infection-induced spike-exposures is equivalent between asthma patients on monoclonal antibodies compared to those treated with conventional therapy.

Schlagwörter

Stichwörter der Autor:innen

IL-5SARS-CoV-2asthmaconventional therapymonoclonal antibody therapy

Autor:innen und Institutionen

  • Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Institute for Hygiene and Microbiology, Julius Maximilian University (JMU) Wuerzburg, Wuerzburg, Germany.
  • Steinbeis-Innovationszentrum Zellkulturtechnik c/o Technical University of Applied Sciences Mannheim, Mannheim, Germany.
  • Department of Pneumology and Critical Care Medicine, Clinic for Thoracic Medicine at Heidelberg University Hospital, Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germ…
  • Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health (CPD), University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.

ORCID-Profile: Giovanni Almanzar, Juliane Mees, Manfred Frey, Felix J F Herth, Marc A Schneider, Frederik Trinkmann

Zitieren

APA

Almanzar, G., Broderdörp, A., Mees, J., Frey, M., Herth, F. J. F., Schneider, M. A., Trinkmann, F., & Prelog, M. (2026). Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy. Journal of Asthma and Allergy, Volume 19, 1-15. https://doi.org/10.2147/jaa.s547038

Vancouver

Almanzar G, Broderdörp A, Mees J, Frey M, Herth FJF, Schneider MA, et al. Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy. Journal of Asthma and Allergy. 2026;Volume 19:1-15. doi:10.2147/jaa.s547038

BibTeX
@article{Almanzar2026,
  author = {Almanzar, Giovanni and Broderdörp, Anna and Mees, Juliane and Frey, Manfred and Herth, Felix J F and Schneider, Marc A and Trinkmann, Frederik and Prelog, Martina},
  title = {Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy},
  journal = {Journal of Asthma and Allergy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--15},
  doi = {10.2147/jaa.s547038}
}
Kostenlos starten →